A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Bristol-Myers Squibb
Study ID
NCT07195682
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986506 — DRUG
    Specified dose on specified days

Study Details

This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.

Key Dates

Start date
Jan 15, 2026
Status verified
Jun 2026
Primary completion
May 3, 2030
Completion
Apr 3, 2031

Study Design

Enrollment
125 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BMS-986506: Part 1A
  • Experimental: BMS-986506: Part 2A
  • Experimental: BMS-986506: Part 2B

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) [ Time Frame: Up to approximately 2 years from first dose of BMS-986506 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (5)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215
Stephanie Berg, Site 0006
617-632-4932
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Martin Voss, Site 0029
646-888-4721
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111
Elizabeth Plimack, Site 0002
215-728-3889
SCRI Oncology PartnersNashvilleTennessee37203
Benjamin Garmezy, Site 0026
713-444-7804
START San AntonioSan AntonioTexas78229
Amita Patnaik, Site 0001
210-593-5250

Find similar trials in Boston, MA

By condition
Kidney cancer
By specialty
OncologyUrology
By research site
Dana-Farber Cancer Institute· Boston, MAMemorial Sloan Kettering Cancer Center· New York, NYFox Chase Cancer Center· Philadelphia, PASCRI Oncology Partners· Nashville, TNSTART San Antonio· San Antonio, TX

Related Studies